The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
HLA-DQA1 * 02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
Abstract
Purpose: Hepatobiliary adverse events (AEs) have been observed in a small proportion of patients with metastatic breast cancer (MBC) treated with lapatinib. This study sought to identify gene variants associated with lapatinib-induced ALT elevation and hepatobiliary AEs. Patients and Methods: A two-stage pharmacogenetic investigation of ALT elevation was conducted in lapatinib-treated patients with MBC. Exploratory marker identification evaluated classical HLA alleles, candidate genes, and genome-wide screening in 37 cases with ALT greater than 3 times the upper limit of normal (ULN) and 286 controls with ALT ≤ 1× ULN, selected from 901 lapatinib-treated patients in 12 trials. Markers achieving prespecified association thresholds were progressed to an independent confirmatory data set of 24 ALT cases and 155 controls selected from a subsequent trial of 374 lapatinib-treated patients. Results: Of 58 variants associated with ALT elevation in the exploratory data set, four exceeded the prespecified significance threshold in the confirmatory analysis. These variants reside in the same MHC genomic locus and include HLA-DQA1*02:01. In the confirmatory study, DQA1*02:01 allele carriage was present in 71% of ALT cases and in 21% of controls (P < .001; odds ratio, 9.0; 95% CI, 3.2 to 27.4). As a predictor of liver safety risk in ALT cases versus noncases, DQA1*02:01 had negative and positive predictive values of 0.97 (95% CI, 0.95 to 0.99) and 0.17 (95% CI 0.10 to 0.26), respectively. Conclusion: These results support a role for immune mechanisms in lapatinib-induced hepatotoxicity. Further work is required to determine whether testing for DQA1*02:01 allele carriage is clinically useful in managing liver safety risk during lapatinib treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
Population Structure and Eigenanalysis
Patterson, N., Price, A. L., & Reich, D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020190 · Cited by 5,280
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Self-citationDanan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Self-citationHLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
MHC class II proteins and disease: a structural perspective
Jones, E. Y., Fugger, L., Strominger, J. L., & Siebold, C. (2006) · Nature Reviews Immunology · doi:10.1038/nri1805 · Cited by 411
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T. M., Meyer, J., & Paulding, C. A. (2010) · Nature Genetics · doi:10.1038/ng.632 · Cited by 388
Heinze, G. (2006) · Statistics in Medicine · doi:10.1002/sim.2687 · Cited by 379
Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., Carlsson, S., Cederbrant, K. E., Gibson, N. J., Armstrong, M., et al. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500458 · Cited by 367
Self-citationManns, M. P., Johnson, E. F., Griffin, K. J., Tan, E. M., & Sullivan, K. F. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113949 · Cited by 363
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350
Sharma, S. K., Balamurugan, A., Saha, P. K., Pandey, R. M., & Mehra, N. K. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2108091 · Cited by 336
Variation analysis and gene annotation of eight MHC haplotypes: The MHC Haplotype Project
Horton, R., Gibson, R., Coggill, P., Miretti, M., Allcock, R. J., Almeida, J., Forbes, S., Gilbert, J. G. R., Halls, K., Harrow, J. L., et al. (2008) · Immunogenetics · doi:10.1007/s00251-007-0262-2 · Cited by 315
Co-amoxiclav jaundice: clinical and histological features and HLA class II association
O'Donohue, J., Oien, K. A., Donaldson, P., Underhill, J., Clare, M., MacSween, R. N. M., & Mills, P. R. (2000) · Gut · doi:10.1136/gut.47.5.717 · Cited by 262
Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., Shimizu, S., Masumoto, H., & Okutani, Y. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500442 · Cited by 185
Flow Cytometric Platform for High-Throughput Single Nucleotide Polymorphism Analysis
Taylor, J. D., Briley, D., Nguyen, Q., Long, K., Iannone, M. A., Li, M.-S., Ye, F., Afshari, A., Lai, E., Wagner, M., et al. (2001) · BioTechniques · doi:10.2144/01303dd04 · Cited by 173
Andrade, R. J., Lucena, M. I., Alonso, A. O., García‐Cortés, M., García-Ruiz, E., Benitez, R. A., Fernández, C. M. A., Peláez, G. I. C., Romero, M., Corpas, R., et al. (2004) · Hepatology · doi:10.1002/hep.20215 · Cited by 154
Fallang, L.-E., Bergseng, E., Hotta, K., Berg‐Larsen, A., Kim, C., & Sollid, L. M. (2009) · Nature Immunology · doi:10.1038/ni.1780 · Cited by 148
Drug-induced liver injury: Hy’s rule revisited
BJORNSSON, E. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.02.012 · Cited by 128
Löhr, H. F., Manns, M. P., Kyriatsoulis, A., Lohse, A. W., Trautwein, C., BÜSCHENFELDE, K.-H. M. Z., & Fleischer, B. (1991) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1991.tb08164.x · Cited by 117
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions
Nelson, M. R., Bacanu, S., Mosteller, M., Li, L.-L., Bowman, C. E., Roses, A. D., Lai, E., & Ehm, M. G. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.4 · Cited by 116
Loriot, Y., Perlemuter, G., Malka, D., Penault-Llorca, F. M., Boige, V., Deutsch, É., Massard, C., Armand, J. P., & Soria, J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1087 · Cited by 110
Lakehal, F., Dansette, P. M., Becquemont, L., Lasnier, E., Delelo, R., Balladur, P., Poupon, R. Y., Beaune, P. H., & Housset, C. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002435 · Cited by 76
TEACH: Tykerb Evaluation After Chemotherapy
Moy, B., & Goss, P. E. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.007 · Cited by 26
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., Day, C. P., Ruiz–Cabello, F., Donaldson, P. T., Stephens, C., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.001 · Cited by 442
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
Metadata
- Authors
- Spraggs, C. F., Budde, L. R., Briley, L. P., Bing, N., Cox, C. J., King, K. S., Whittaker, J. C., Mooser, V. E., Preston, A. J., Stein, S. H., & Cardon, L. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-20
- Volume
- 29
- Issue
- 6
- Pages
- 667-673
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163278353
- Cited by
- 275
- References
- 26
- FWCI
- 27.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.